Baker Bros. Advisors 13F: Adds $133M to GRAIL (GRAL) Stake

Baker Bros. Advisors Expands GRAIL Position

Baker Bros. Advisors raised its stakes in GRAIL, Inc. GRAL by picking up 1,943,281 shares during the period ending May 15, 2026. According to a Form 13F filing with the SEC, the firm grew its position by 93.2% to end the quarter with 4,028,614 shares. Those holdings carried an estimated value of $275.0 million based on the period's data. Institutional filings look backward at past activity and might not reflect the fund's current holdings today.

GRAIL Stock and Market Standing

Shares of GRAIL trade around $68.27 as the healthcare firm navigates its cancer screening and diagnostic operations. The company carries a market capitalization near $4.82 billion. Because the firm posted a negative per-share earning of -$9.69, it lacks a standard price-to-earnings multiple. Investors note a beta of 3.25, indicating wider price swings than the broader market over time.

Wall Street Analyst Coverage and Targets

Major financial firms recently adjusted their outlooks and price targets on the healthcare developer. On October 13, 2026, Morgan Stanley kept its equal-weight rating while setting a $120.00 target, up from $60.00. On the same day, TD Cowen maintained a buy rating and raised its target to $180.00 from $88.00. UBS held a buy rating on October 2, 2026, with a target of $175.00. Guggenheim kept a buy rating on October 1, 2026, moving its target to $155.00. Canaccord Genuity maintained a buy rating on September 28, 2026, and set a $150.00 target. Mizuho held a neutral rating on September 25, 2026, adjusting its target to $100.00. Baird kept an outperform rating on September 22, 2026, with an $118.00 target. RBC Capital initiated coverage with a sector perform rating and an $84.00 target on September 17, 2026. Across ten analyst opinions, the consensus view stands at a buy with a mean price target of $82.40.

Inside GRAIL Operations

GRAIL, Inc. operates as a commercial-stage healthcare company focused on multi-cancer early detection testing. Headquartered in Menlo Park, California, the firm provides the Galleri screening test designed for asymptomatic individuals over fifty years old. Its precision oncology portfolio includes methylation-based platforms for disease prognostication, minimal residual disease detection, and recurrence monitoring. The company employs roughly 910 people and continues to support clinical studies and therapy development.

What to Watch Next for GRAIL

Market observers will check subsequent SEC filings to track whether Baker Bros. Advisors continues building its position in the diagnostics provider. The company's next earnings release is scheduled for November 11, 2026, which will provide updated revenue and financial metrics for investors.